alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 226–250 of 571 studies · free to read · tagged Digital Tools (page 10 of 23) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

ALZENET: Deep learning-based early prediction of Alzheimer's disease through magnetic resonance imaging analysis

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Telematics and Informatics Reports 2025-02-14

Alzheimer's Disease (AD) is a particular form of dementiacharacterized by a steady decline in brain function and cognitive abilities, leading to memory loss, disorientation, and trouble doing daily tasks. 3 key findings →

Participants: 6,400 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine learning to predict dementia for American Indian and Alaska native peoples: a retrospective cohort study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Lancet Regional Health - Americas 2025-02-13

The study cohort included 17,398 AI/AN adults aged ≥ 65 years who were dementia-free at baseline, of whom 59.8% were female. 5 key findings →

Participants: 17,398 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Top-funded digital health companies offering lifestyle interventions for dementia prevention: Company overview and evidence analysis

✓ Peer-reviewed alzhub usefulness score 48 out of 100. PLoS ONE 2025-05-05

The ten top-funded companies offering DDLS received a total funding of EUR 128.52 million, of which three companies collected more than 75%. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neuropsychopharmacology 2026-01-19

Vascular Cognitive Impairment and Dementia (VCID), the second most common form of dementia, is becoming increasingly prevalent worldwide. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparison of Deep Learning and Traditional Machine Learning Models for Predicting Mild Cognitive Impairment Using Plasma Proteomic Biomarkers

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal of Molecular Sciences 2025-03-08

Mild cognitive impairment (MCI) is a clinical condition characterized by a decline in cognitive ability and progression of cognitive impairment. 3 key findings →

Participants: 239 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

WMH ‐ DualTasker : A Weakly Supervised Deep Learning Model for Automated White Matter Hyperintensities Segmentation and Visual Rating Prediction

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Human Brain Mapping 2025-04-15

White matter hyperintensities (WMH) are neuroimaging markers linked to an elevated risk of cognitive decline. 2 key findings →

Participants: 60 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglial activation in the right amygdala-entorhinal-hippocampal complex is associated with preserved spatial learning in AppNL-G-F mice

✓ Peer-reviewed alzhub usefulness score 47 out of 100. NeuroImage 2020-12-29

Elevated microglial activation in the right amygdala-entorhinal-hippocampal complex of App NL-G-F mice is associated with better spatial learning. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests

✓ Peer-reviewed alzhub usefulness score 47 out of 100. BMC research notes 2011-08-17

These methods may be used to improve accuracy, sensitivity and specificity of Dementia predictions from neuropsychological testing. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ethical concerns with the use of intelligent assistive technology: findings from a qualitative study with professional stakeholders

✓ Peer-reviewed alzhub usefulness score 47 out of 100. BMC medical ethics 2019-12-19

Our findings indicate a general agreement among professional stakeholders on the ethical promises and challenges raised by the use of IATs among older and disabled users. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Using machine learning to quantify structural MRI neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Human brain mapping 2020-07-02

Biomarkers for dementia of Alzheimer's type (DAT) are sought to facilitate accurate prediction of the disease onset, ideally predating the onset of cognitive deterioration. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying incipient dementia individuals using machine learning and amyloid imaging

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging 2017-07-11

Identifying individuals destined to develop Alzheimer's dementia within time frames acceptable for clinical trials constitutes an important challenge to design studies to test emerging disease-modifying therapies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Applications of artificial intelligence to aid early detection of dementia: A scoping review on current capabilities and future directions

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of biomedical informatics 2022-02-17

Seventy percent of cases are due to Alzheimer's disease (AD) pathology and there is a 10-20 year 'pre-clinical' period before significant cognitive decline occurs. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. NeuroImage. Clinical 2021-06-04

This work validates the generalizability of MRI-based classification of Alzheimer's disease (AD) patients and controls (CN) to an external data set and to the task of prediction of conversion to AD in individuals with mild cognitive impairment (MCI). 2 key findings →

Participants: 199 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Implementing a peer-support programme by group videoconferencing for isolated carers of people with dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of telemedicine and telecare 2019-10-01

Providing peer-support groups using telehealth may have the potential to develop self-sustaining peer networks for isolated caregivers of people with dementia. 1 key finding →

Participants: 28 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Free radical biology & medicine 2009-10-23

Numerous studies have demonstrated oxidative damage in the central nervous system in subjects with Alzheimer disease and in animal models of this dementing disorder. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of neuroinflammation 2004-12-08

Anti-Abeta immunotherapy in transgenic mice reduces both diffuse and compact amyloid deposits, improves memory function and clears early-stage phospho-tau aggregates. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A novel neuroimaging based early detection framework for alzheimer disease using deep learning

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Scientific Reports 2025-07-02

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that significantly impacts cognitive function, posing a major global health challenge. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An explainable and efficient deep learning framework for EEG-based diagnosis of Alzheimer's disease and frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in Medicine 2025-07-15

The early and accurate diagnosis of Alzheimer's Disease and Frontotemporal Dementia remains a critical challenge, particularly with traditional machine learning models which often fail to provide transparency in their predictions, reducing user confidence and treatment effectiveness. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed